Procter & Gamble Health Net Profit Jumps 45% to ₹96.15 Crore

Procter & Gamble Health Ltd. has announced a standalone net profit of ₹96.15 crore for the first quarter of fiscal year 2027, marking a 45% increase from ₹66.18 crore in the same quarter last year.

The company's revenue from operations for the quarter ended June 30, 2026, stood at ₹363.71 crore, a 7.37% increase from ₹338.74 crore in the corresponding period of the previous fiscal year.

Total income for Q1 FY27 reached ₹367.59 crore, up from ₹342.77 crore in Q1 FY26. Total expenses for the quarter increased to ₹270.27 crore from ₹253.96 crore year-on-year.

The quarter's results include an exceptional gain of ₹31.80 crore from the sale of an office premises property in Worli. The property was sold for ₹33.34 crore, with a carrying amount of ₹1.54 crore.

Basic and diluted earnings per share (after exceptional items) for the quarter ended June 30, 2026, were ₹57.92, an increase from ₹39.87 in the same quarter last year.

The unaudited financial results for the quarter were reviewed by the Audit Committee and approved by the Board of Directors on August 6, 2026. Haribhakti & Co. LLP, the statutory auditors, conducted a limited review of the financial statements and concluded that nothing came to their attention that would cause them to believe the statement contained any material misstatement.

Procter & Gamble Health's performance is a significant indicator of the company's growth in the Indian market. The increase in net profit and revenue from operations suggests a strong demand for the company's products.

The company's decision to sell its office premises property in Worli also indicates a strategic move to optimize its resources and focus on its core business.

The appointment of India-born Shailesh Jejurikar as the next Chief Executive Officer of Procter & Gamble Company is also a significant development, highlighting the company's commitment to diversity and inclusion.

Overall, Procter & Gamble Health's Q1 FY27 results demonstrate a positive trend for the company, with increased revenue and net profit. This growth is expected to continue, driven by the company's strong product portfolio and strategic decisions.

The Indian FMCG market is highly competitive, and Procter & Gamble Health's performance is a testament to the company's ability to adapt and innovate in a rapidly changing environment. As the company continues to expand its operations and product offerings, it is likely to remain a major player in the Indian market.

In terms of significance for Mumbai, Procter & Gamble Health's growth is a positive indicator for the city's economy, as it suggests an increase in employment opportunities and economic activity. The company's decision to sell its office premises property in Worli also highlights the city's attractiveness as a hub for business and commerce.

In conclusion, Procter & Gamble Health's Q1 FY27 results are a significant development for the company and the Indian FMCG market. The company's growth and strategic decisions are expected to have a positive impact on the economy and employment opportunities in Mumbai.